Introduction
Materials and methods
Literature search
Inclusion and exclusion criteria
Data extraction and analysis
Results
Identification of PROMs
Abbreviation type | Objective | Domains covered | |
---|---|---|---|
SF-36 | Generic | Measuring HRQoL of individuals with several chronic health conditions | 36-questions on physical functioning, physical role, pain, general health, vitality, social function, emotional role and mental health |
SF-12 | Generic | Measuring HRQoL of individuals with several chronic health conditions with substantially fewer questions than the SF-36 | 12-Questions on physical functioning, role functioning, social functioning, mental health, health perceptions, pain |
EQ-5D (3L or 5L)* | Generic | A simple, generic measure of health for clinical and economic appraisal | 5-Items on mobility, self-care, usual activity, pain/discomfort, and anxiety/depression and a visual analogue scale on self-rated health |
PROMIS-10 | Generic | Measurements of symptoms, functioning, and healthcare-related quality of life (HRQoL) for a wide variety of chronic diseases and conditions | 10-Questions on overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life |
LASA | Generic | General measures of global QOL dimensional constructs in numerous settings | 5-Questions on physical well-being, emotional well-being, spiritual well-being, intellectual well-being, and overall QOL |
WHOQOL-BREF | Generic | Assess the individual’s perceptions in the context of their culture and value systems, and their personal goals, standards, and concerns | 26-Questions on global items, physical health, psychological health, social relationships, environment QOL |
EORTC-QLQC30 | Cancer specific | Assessing the HRQoL of cancer patients participating in international clinical trials | 30-Questions on functional scales, symptom scales, global health status/QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients and perceived financial impact of the disease |
EORTC-QLU-C10D | Cancer specific | Developed to capture cancer patients’ QoL and to relate it to survival time and costs of treatment in health economic studies | 10-Items on physical functioning, role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems |
GERD-Q | Disease symptoms specific | Determine the presence or absence of symptoms of GERD in the general population | 6-Questions on symptoms of GERD |
BSI-18 | Disease symptoms specific | Assessment of psychological distress | 18-Questions on somatization, anxiety, and depression |
GSRS | Disease symptoms specific | A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease | 15-Qestions on reflux, abdominal pain, indigestion, diarrhea, and constipation |
GIQLI | Disease symptoms specific | Assess QoL specific for the gastrointestinal tract | 36-Questions on GI symptoms, emotion, physical function, social function, and medical treatment |
SCL-90 | Disease symptoms specific | Evaluate a broad range of psychological problems and symptoms of psychopathology | 90-Items on somatization, obsessive compulsive disorder, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism |
GERD-HRQL | Disease symptoms specific | Measure symptomatic change as a result of medical or surgical treatment of GERD | 16-Questions on measuring symptom severity in GERD |
QOLRAD | Disease symptoms specific | Monitor changes in HRQOL in patients suffering from heartburn and dyspepsia | 25-Questions on emotional distress, sleep disturbances, food/drink problems, physical/social functioning, vitality |
RDQ | Disease symptoms specific | Assess the frequency and severity of heartburn, regurgitation, and dyspeptic complaints and to facilitate the diagnosis of GERD in primary care | 12-Items on regurgitation, heartburn, and dyspepsia |
BE QOL | Disease symptoms specific | Not defined | 10-Questions on esophagostomy worry, adenocarcinoma worry, esophagus general worry, depression, daily QoL, amount of stress, difficulty to sleep, work or family life negatively impacted and worry dying due to esophagus |
The ogilvie grading scale | Disease symptoms specific | To determine level of dysphagia | 5-Items on dysphagia |
QLQ-OG25 | Cancer symptom specific | Assess QOL in patients with esophageal or gastric cancer and esophagogastric junction carcinoma | 25-Questions on dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety |
EORTC-QLQ OES18 | Cancer symptom specific | Assess QOL in patients with esophageal cancer | 18-Questions on esophageal functional, symptomatic scales, and the global QoL |
TPS | Trust in physician | Assess each patient’s interpersonal trust in his primary care physician within the context of the management of chronic disease | 11-Items on trust in physician |
IES | Endoscopic burden | Assess current subjective distress for any life event | 15-Items on episodes of intrusion, episodes of avoidance |
DIS | Endoscopic burden | Measure of avoidance of and difficulty in tolerating somatic sensations | 7-Items on ability to tolerate discomfort and pain, and avoidance of physical discomfort |
PSQI | Sleeping difficulties | Assess sleep quality over a 1-month time interval | 19-Items on subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction |
Berlin-Q | Sleeping difficulties | Identifying patients with sleep apnea in primary care setting | 10-Questions on snoring behavior, wake time sleepiness or fatigue, obesity, hypertension |
HADS | Anxiety and depression | Measure symptoms of anxiety and depression | 14-Items on anxiety and depression |
B-IPQ | Illness perceptions | Assess cognitive and emotional representations of illness | 8-Questions on cognitive illness, emotional perceptions, illness comprehensibility. And an open-ended response with three most important self-perceived causal factors of their illness |
WOCS | Fear of cancer | Undefined | 4-Questions on esophageal cancer in particular |
CWS | Fear of cancer | Measure cancer-specific worry and impact of worry on daily functioning | 8-Questions on worry and impact of worry on daily functioning |
Author, Year | Eloubeidi, 2000 | Kulig, 2003 | Gerson, 2005 | Kruijshaar, 2006 | Essink-Bot, 2007 | Reddy, 2020 | Gerson, 2007 |
---|---|---|---|---|---|---|---|
Level of evidence | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Analyse sample | NDBE = 88, GERD = 88 | NDBE = 702, NERD = 2853 ERD = 2660 | NDBE = 40, GERD = 118 | NDBE = 180 | NDBE = 180, NS = 214, EAC = 82 | DBE/EAC ET = 239 DBE/EAC surgery = 153 | NDBE/DBE = 60 GERD = 40 |
AIM | (1) To compare HRQL of patients with BE and patients with GERD who do not have BE; (2) to compare HRQL of GERD patients to that of normative data for the US general population; (3) to examine the impact of GERD symptom severity and frequency on HRQL in these patients | Describe the impact of GERD on the quality of life, to assess the changes in the QoL after 2 weeks of treatment with PPI and to define the factors that can predict these changes | To derive health state utilities for patients with chronic reflux symptoms who required daily medication for adequate symptom control | To explore the burden of upper gastro-intestinal endoscopy as perceived by patients | Analyze potential determinants of the perceived burden of upper GI endoscopy by comparing BE patients with two additional patient groups, i.e., patients with non-specific upper GI symptoms (NS) and patients with a recent diagnosis of cancer of the upper GI tract (CA) | Compare long-term HR-QOL associated with ET or esophagostomy among patients with HGD or T1a EAC | To determine whether time trade of values would differ in patients with BE when patients were asked to trade away potential risk of esophageal adenocarcinoma rather than chronic heartburn symptoms |
Baseline characteristics | Age, race, gender, nicotine use, alcohol use, PPI use, Charlson index (comorbidities), psychosomatic symptom checklist | Age, gender education, marriage status, comorbidity, family history of GERD, nonsteroidal anti-inflammatory drug use, esophagitis, BMI | Age, gender, years of reflux, comorbidity, PPI use, 24-Kr potential of hydrogen test, and esophageal motility assessment | Age, gender, marital status, employment status, education, number of endoscopies, histology, reflux esophagitis, PPI use, general health | Age, gender, employment, civil status, education, sedation, hospital, endoscopy number | Age, gender, length BE diagnosis, histology, comorbidity | Age, gender, years of reflux, comorbidity, years on PPI, race, site of care, income |
PROMs used | 2 | 3 | 2 | 3 | 4 | 2 | 3 |
Validated PROMs | SF-36 GERD-Q | SF-36 QOLRAD RDQ | QOLRAD GSRS | EQ-5D-3L IES HADS | EQ-5D-3L IES HADS | EORTC-QLQ-C30 EORTC-QLQ-OES18 | SF-36 QOLRAD RDQ |
Non-validated questionnaires | N/A | N/A | N/A | Non-validated questions on disease symptoms with Likert scale | Non-validated questions on disease symptoms and endoscopic burden with Likert scale | N/A | N/A |
Factors covered | 7/18 | 8/18 | 7/18 | 3/18 | 3/18 | 7/18 | 8/18 |
Author, Year | Lippmann, 2009 | Cooper, 2009 | Miller, 2010 | Rosmolen, 2010 | Shaheen, 2010 | Schembre, 2010 | |
---|---|---|---|---|---|---|---|
Level of evidence | 3 | 3 | 3 | 3 | 2 | 3 | |
Analyse sample | NDBE = 168, GERD = 361 | NDBE = 151 | NDBE/DBE = 489, EAC = 212 | DBE/EAC ET = 81 EAC surgery = 33 | DBE = 127 | DBE = 40 | |
AIM | To isolate any decrease in HRQoL associated with Barrett’s esophagus by comparing BE patients to GERD patients with similar GERD symptom severity, and to measure any additional psychological distress that may be associated with BE, which could potentially be attributed to cancer risk. Additionally, we sought to determine whether any differences were present in quality of life based on gender and presence of erosive disease | Examine the experience of patients undergoing endoscopic surveillance for BO, their levels of anxiety and depression, and quality of life and how the relationship with their physicians influences these factors | To quantify the association of marital status and changes in QOL over time in patients with EC and patients with BE | To explore QOL, fear of cancer recurrence, and anxiety in patients with a Barrett’s esophagus treated for HGD or early cancer in the past, by comparing these outcomes between endoscopically and surgically treated patients | To evaluate QoL before and after endoscopic treatment of dysplastic BE with RFA | Attempt to better understand the relative impact of esophagestomy and ET on patients’ QOL after therapy and recovery are complete | |
Baseline characteristics | Age, gender race, alcohol use, tobacco use, anti- reflux surgery, BMI, medication, comorbidities, prior mental health status | Age, gender, number of gastroscopies, length BE | Age, gender, marriage status, histology, surgical treatment, chemotherapy | Age, gender, comorbidity. Endoscopy treatment: type of treatment, duration of the treatment, HGD/early cancer during follow-up. Surgically treated patients: type of surgical resection and reconstruction, length of hospital admission, complications, anastomotic stenosis, and histology of the resected specimen | Age, gender, race, BMI, Length of BE, histology, time since diagnosis of BE, time since diagnosis of dysplasia | Age, gender, American Society of Anesthesiologists score, BE length | |
PROMs used | 4 | 3 | 1 | 4 | 1 | 2 | |
Validated PROMs | SF-36 GIQLI SCL-90-R GERD-HRQL | SF-36 TIPS HADS | LASA | SF-36 EORTC-QLQ-C30 EORTC-QLQ-OES18 HADS | SF-36 GIQLI | ||
Non-validated questionnaires | N/A | Non-validated question on trust Physician, fear of cancer and knowledge with and without Likert scale | N/A | WOCS | Eight non-validated questions with range scale | N/A | |
Factors covered | 10/18 | 3/18 | 1/18 | 8/18 | 0/18 | 9/18 |
Author, Year | Crockett, 2012 | Vela, 2013 | Rosmolen, 2017 | Chang, 2016 | Lee, 2017 | Baldaque-silva, 2017 | Britton, 2020 |
---|---|---|---|---|---|---|---|
Level of evidence | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Analyse sample | NDBE = 235 | NDBE = 63, GERD = 83 Control = 75 | NDBE = 44, DBE/EAC ET = 42 DBE/EAC surgery = 21 Advanced EAC surgery = 19 | NDBE = 84, control = 168 | NDBE = 139 | NDBE = 54 | NDBE = 305 DBE = 48 GORD = 131 Colonic- polyp = 150 Control = 47 |
AIM | To identify predictors of over- or under-utilization of endoscopic surveillance including demographic factors, quality of life, healthcare numeracy, risk perception, and other health behaviors | (1) to compare the effect of GERD and BE on sleep quality and (2) to assess whether the association between sleep quality and GERD or its more severe form (i.e., BE) is independent of obstructive sleep apnea | Investigate the overall QOL and the fear of cancer recurrence at multiple time points and included larger cohorts of patients | Determine whether HRQOL of BE patients were worse than healthy referents in the ethnic Chinese population in Taiwan, adjusted for potential confounding factors | To investigate HRQoL in a Chinese population with BE | Determine the impact of upward titration of PPI on acid reflux, symptom scores, and histology, compared to clinically successful fundoplication | Assess HRQoL in patients with NDBE and endoscopically treated DBE compared with other common gastrointestinal disorders and healthy individuals |
Baseline characteristics | Age, gender, race, site, education, income, employment, family history BE and EAC, insurance, duration of BE | Age, gender, race, smoking, BMI, recruitment source | Age, gender, comorbidity, type of treatment, treatment-related complications, treatment time, histology, recurrence during FU, additional treatment | Age, gender, BMI, comorbidity, marital status, education, employment, history of smoking and drinking | Age, BMI, Waist (cm), gender BE length, esophagocardiac junction, histology | Age, gender BMI, smoking, BE length | Age, gender, histology, employment, family history, career, smoking, PPI, anti-depressant, BE length, co-morbidities |
PROMs used | 2 | 3 | 4 | 1 | 3 | 1 | 4 |
Validated PROMs | SF-36 GERD-HRQL | GERD-Q PSQI BQ | SF-36 EORTC-QLQ-C30 EORTC-QLQ-OES18 HADS | WHOQOL-BREF | SF-12 RDQ HADS | GERD-HRQL | SF-36 GSRS CWS HADS |
Non-validated questionnaire | Non-validated questions on disease symptoms, anxiety and worry with Likert scale | N/A | WOCS | N/A | N/A | N/A | N/A |
Factors covered | 7/18 | 6/18 | 8/18 | 3/18 | 7/18 | 7/18 | 7/18 |
Author, Year | Han, 2018 | Ende-van Loon, 2018 | Rosmolen, 2019 | Balamu, 2019 | Peerally, 2019 | Schwameis, 2020 | Hauge, 2020 |
---|---|---|---|---|---|---|---|
Level of evidence | 3 | 3 | 2 | 3 | 2 | 3 | 3 |
Analyse sample | NDBE/DBE = 193 | NDBE = 158 | NDBE = 49, DBE = 47 | NDBE/DBE/EAC = 97 | DBE/EAC = 76 | DBE/EAC = 40 | DBE/EAC = 86 |
AIM | (1) Measure QOL impairment among patients with BE referred for endoscopic eradication therapy; (2) identify factors associated with reduced QOL | To assess the EAC risk perceived by patients with NDBE in an endoscopic surveillance program and to associate these perceived EAC risks with illness perception and QoL | QOL and illness perceptions with confirmed low-grade dysplasia, comparing surveillance and ablation | Investigate HRQoL and health utility scores for common progression states in patients | Randomized pilot study of the 2 techniques comparing dysplasia clearance, BE eradication, recruitment, retention, and health economic analysis | To evaluate the workload associated with endotherapy, the frequency and type of recurrence, long-term QOL, and late oncologic outcomes in a group of patients that were followed for a minimum of 5 years by 1 treating physician | To evaluate the treatment of dysplasia and superficial esophageal cancer with endoscopic mucosal resection and/or radio frequency ablation and the post-procedural HRQL |
Baseline characteristics | Age, gender, race, family history of BE and/or EAC, PPI use, duration of BE, length of BE (cm), histology, presence of Hiatus, Hernia Diaphragm, BMI | Age, gender BE diagnosis, marital status, education, employment status, comorbidity, cancer in friends or family | Age, gender length of BE, time since diagnosis of BE in years, time since diagnosis of dysplasia in years, PPI use, Number of comorbidities | Age, gender comorbidity, treatment history previous 12 months, smoking, race, born in Australia, smoking, comorbidities, treatment characteristics | Age, gender, BMI, BE length, histology | Age, gender, histology, no. Treatments, BE length, follow-up length | Age, gender, BE length, histology |
PROMs used | 4 | 3 | 4 | 5 | 3 | 3 | 3 |
Validated PROMs | PROMIS-10 Gerd-Q DIS BSI | SF-36 GERD-Q B-IPQ | SF-36 EORTC-QLQ-C30 EORTC-QLQ-OES18 B-IPQ | SF-6D SF-36 EQ-5D-5L EORTC-QLU-C10D EORTC-QLQ-C30 | EQ-5D EORTC-QLQ-C30 EORTC-QLQ-OES18 | SF-36 GIQLI | EORTC-QLQ-C30 QLQ-OG25 The Ogilvie grading scale |
Non-validated questionnaire | N/A | N/A | N/A | N/A | Non-validated questions on disease symptoms | Non-validated questions on disease symptoms | N/A |
Factors covered | 7/18 | 9/18 | 7/18 | 3/18 | 8/18 | 9/18 | 7/18 |
Identification of influencing factors according to BE patients
Author, Year, Country | Ende-van Loon, 2020, NL | Britton, 2018, UK | Arney, 2014, USA | Griffiths, 2011, UK | ||
---|---|---|---|---|---|---|
Aim | To assess the factors influencing HRQOL according to NDBE and DBE patients | To identify and explore factors impacting BO patients’ health-related quality of life, follow-up needs and views on new models of follow-up care | To identify elements of the EGD experience that frame patients’ memories and overall perceptions of surveillance | To explore patients’ views and perspectives on their experience of living with Barrett’s columnar-lined oesophagus (CLO) and being part of an endoscopic surveillance program | ||
Method | Focus group | Exploratory qualitative approach was adopted using semi-structured, in-depth, one-to-one interviews | structured, in-depth, qualitative interviews | Qualitative semistructured interviews | ||
Sample | NDBE = 16 DBE/EAC ET = 17 | NDBE = 20 | NDBE/DBE = 20 | NDBE = 22 | ||
Quality score | 10/10 | 10/10 | 8/10 | 7/10 | ||
1. Mental health | ||||||
Fear of cancer | ✓ | ✓ | ✓ | ✓ | ||
Anxiety | ✓ | ✓ | ✓ | |||
Trust in physician | ✓ | ✓ | ✓ | |||
Sense of control | ✓ | ✓ | ✓ | ✓ | ||
Uncertainty | ✓ | ✓ | ✓ | ✓ | ||
Worry | ✓ | ✓ | ✓ | |||
Burden of endoscopy | ✓ | ✓ | ✓ | |||
Knowledge and understanding | ✓ | ✓ | ✓ | ✓ | ||
2. Physical health | ||||||
Gastrointestinal symptoms | ✓ | ✓ | ✓ | ✓ | ||
Reflux | ✓ | ✓ | ||||
Regurgitation | ✓ | |||||
Dyspepsia | ✓ | |||||
Dysphagia | ✓ | |||||
Epigastric pain | ✓ | |||||
Sleeping difficulties | ✓ | |||||
Diet/lifestyle | ✓ | |||||
Use of medication | ✓ | ✓ | ✓ | |||
3. Social health | ||||||
Support of family and friends | ✓ |
Coverage of factors in HRQOL PROMs relevant to patients
Fear of cancer | Anxiety | Trust in physician | Sense of control | Uncer-tainty | Worry | Burden of endoscopy | Knowledge and understanding | Reflux/heartburn | Regurgitation | Dyspepsia | Dysphagia | Epi-gastric pain | Sleeping difficulties | Diet/lifestyle | Use of medication | Social Support | Total factors ✓ (±) | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GIQLI | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 9 | |||||||||||
GERD-HRQL | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ± | ✓ | 7 (1) | ||||||||||||
GERD-Q | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||||||||||||
QLQ-OG25 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | 6 | ||||||||||||||
QOLRAD | ✓ | ± | ✓ | ✓ | ✓ | ✓ | ± | 5 (+ 2) | |||||||||||||
RDQ | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||||||||||||
EORTC-QLQ OES18 | ✓ | ✓ | ✓ | ✓ | ✓ | 5 | |||||||||||||||
GSRS | ✓ | ✓ | ✓ | ✓ | 4 | ||||||||||||||||
WHOQOL-BREF | ✓ | ± | ✓ | ± | ✓ | 3 (2) | |||||||||||||||
SCL-90 | ✓ | ✓ | ± | ✓ | 3 (1) | ||||||||||||||||
B-IPQ | ± | ✓ | ✓ | ✓ | 3 (1) | ||||||||||||||||
EORTC-QLQC30 | ✓ | ± | ✓ | ± | 2 (2) | ||||||||||||||||
CWS | ✓ | ✓ | 2 | ||||||||||||||||||
HADS | ✓ | ✓ | 2 | ||||||||||||||||||
EORTC QLU-C10D | ± | ✓ | ± | 1 (2) | |||||||||||||||||
PROMIS-10 | ✓ | ± | ± | 1 (2) | |||||||||||||||||
EQ-5D | ✓ | ± | 1 (1) | ||||||||||||||||||
IES | ± | ✓ | 1 (1) | ||||||||||||||||||
BSI-18 | ✓ | 1 | |||||||||||||||||||
TPS | ✓ | 1 | |||||||||||||||||||
LASA | ✓ | 1 | |||||||||||||||||||
PSQI | ✓ | 1 | |||||||||||||||||||
Berlin-Q | ✓ | 1 | |||||||||||||||||||
The ogilvie grading scale | ✓ | 1 | |||||||||||||||||||
DIS | ± | ± | ± | 0 (3) | |||||||||||||||||
SF-36 | ± | ± | 0 (2) | ||||||||||||||||||
SF-12 | ± | ± | 0 (2) | ||||||||||||||||||
SF-6D | ± | ± | 0 (2) |